Opportunities for Aligning Prescription Drug Affordability Boards and Cost-Growth Benchmarks

This commentary highlights how states have advanced two separate but related initiatives to tackle rising healthcare costs: cost-growth benchmarks to track and contain overall healthcare spending; and prescription drug affordability boards to conduct reviews of high-cost prescription drugs and set limits on what can be paid for these drugs in the future. Some states have been considering the similarities and differences in these approaches as well as opportunities for alignment across the initiatives.